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Sphingosine kinases 1 and 2 (SK1 and SK2) are proto-oncogenic isozymes expressed
in many human tumors and associated with chemoresistance and poor prognosis.
They are well-recognized therapy targets and their inhibition was shown to induce
tumor volume reduction and chemosensitization in multiple cancer models. Oncogenic
signaling is extremely complex and often cross-regulated. Designing molecular therapies
and their combinations requires rational approaches to avoid redundant targeting or
developing resistance. In this study, we have performed RNA transcriptome microarray
analysis of two breast and two prostate metastatic cancer cell lines treated with
siRNAs targeting SK1 or SK2. In prostate cancer cell lines SK1 knockdown (KD)
has significantly changed expression of several genes including downregulation of
NSUN2, G3BP2 and upregulation of ETS1. SK2 KD also affected expression of multiple
genes including downregulation of CAPZA1 NSUN3 and ADPGK and upregulation of
VDAC1, IBTK, ETS1, and MKNK2. Similarly, in breast cancer cells SK1 KD led to
downregulation of NSUN2, NFATC3, CDK2, and G3BP2 and upregulation of GTF2B,
TTC17, and RAB23. SK2 KD in breast cancer cells has decreased expression of ITGAV
and CAPZA1 and increased expression of GTF2B and ST13. Gene-set enrichment
analysis of known biochemical pathways showed that in prostate and breast cell
lines SKs KD have altered multiple pathways. SK1 KD altered chromatin assembly,
regulation of G1/S transition and mitosis, Wnt and MAP kinase signaling and cell
motility. SK2 KD altered RAS protein signal transduction, regulation of MAP kinase and
serine/threonine kinase activity, cell motility, small GTPase mediated signal transduction
and phosphatidylinositol 3-kinase (PI3K) signaling. Through genome-wide microarray
analysis, we have identified important molecular pathways affected by SK1 and SK2 KD.
It appears that while KD of both genes leads to a decrease in individual pro-tumorigenic
genes, there is a universal cellular response resulting in upregulation of several known
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pro-survival and pro-tumorigenic pathways such as MAPK, RAS, and PI3K, which may
mediate cancer resistance to anti-SKs therapies. Our data point out to the potential
advantage of certain molecular therapy combinations in targeting prostate and breast
cancer. Further signaling studies are required to confirm the individual involvement of
identified pathways.
Keywords: sphingosine kinase, gene knockdown, DNAmicroarray, transcriptome, breast cancer, prostate cancer,
molecular targets, targeted therapy
INTRODUCTION
Sphingosine kinases 1 and 2 (SK1 and SK2) are proto-oncogenic
enzymes expressed in multiple human tumors (Alshaker et al.,
2013). They convert proapoptotic lipid second messenger
sphingosine to anti-apoptotic sphingosine-1-phosphate. SKs
display different subcellular localization and tissue expression
patterns. SK1 is a constitutively active cytosolic enzyme, that
translocates to the plasma membrane upon phosphorylation at
Ser225. SK2 is localized mainly in the nucleus where it has a role
in DNA synthesis and histone H3 acetylation (Song et al., 2018).
There is compelling evidence that SK1 activation contributes
to cancer progression and leads to oncogenic transformation,
increased tumor growth and impairment of apoptosis (reviewed
in Alshaker et al., 2013; White et al., 2016). SK1 is a tumor-
associated enzyme: high levels of SK1 expression have been
shown in various human tumors such as brain, breast, colon,
lung, ovary, stomach, uterus, kidney, rectum, and small intestine,
where they enhance tumor neovascularization and metastatic
potential by promoting motility and invasion of cancer cells
(Cuvillier, 2007; Shida et al., 2008; Pyne et al., 2012). High
levels of SK1 expression or activity are associated with a
poor prognosis in several human cancers, making it a key
pathway in the search for targeted therapies (Pyne et al., 2012).
SK2 is predominantly localized to cell organelles and its role
in cell proliferation/apoptosis is less well studied. However,
several studies showed a critical role of SK2 for epidermal
growth factor-stimulated migration of breast cancer cells,
growth of tumor xenografts and lung cancer chemoresistance
(Song et al., 2018).
Multiple SK1 and SK2 inhibitors have been synthesized and
assayed in different biological systems. Selective SK1 inhibitors
such as SK1-I or SK-F have been demonstrated to efficiently
induce apoptosis in cancer cells (Paugh et al., 2008; Alshaker
et al., 2018). A sphingosine analog FTY720 was shown to
inhibit SK1 and induce cancer cell apoptosis (Wang et al.,
1999; Permpongkosol et al., 2002), chemo- and radiosensitization
(Pchejetski et al., 2010; Alshaker et al., 2017; Wang et al., 2017).
Several studies have indicated an anti-tumorigenic role of a
specific SK2 inhibitor ABC294640 (Antoon et al., 2011; Beljanski
et al., 2011; Song et al., 2018).
Oncogenic signaling pathways are complex. Intervention
with a single pathway usually leads to multiple pathways
being affected due to cross-regulation. Based on this rationale,
identifying signaling “hubs” has become popular in molecular
therapy design, hoping that by targeting one key molecule,
multiple signaling pathways can be regulated. This, however,
can lead to undesirable side effects. Furthermore, targeting
only one pathway does not always lead to desired effects
due to the presence of parallel signaling pathways leading
to the same end-point, prompting the use of combined
therapies. Care should be taken in the creation of combined
therapeutic interventions utilizing compounds that could
target independent or compensatory pathways and therefore
have synergistic effects. The rationale for such combinations
could be derived from studying the gene expression and
pathways regulation.
In this study, we have used for the first time RNA
transcriptome microarray technology to investigate the
transcriptome-wide effects of SK1 and SK2 downregulation.
This approach mimics the therapeutic targeting of SKs by
inhibitors and allows mapping the affected/unaffected signaling
cascades. Our data provide useful insight for creating more
robust therapeutic combinations for cancer targeting.
MATERIALS AND METHODS
Cell Culture and Reagents
Human breast cancer cell lines MDA-MB-231 and BT-549
and human prostate cancer cells lines PC-3 and DU145 were
purchased from ATCC (Manassas, VA, United States), and
maintained in RPMI with 10% FCS, 50 U/ml penicillin, 50 µg/ml
streptomycin and 2 mM glutamine (Sigma-Aldrich, St. Louis,
MO, United States). Cell lines were kept in culture for up to 30
passages. Cells were seeded to reach 70–80% confluence by the
end of the treatment. All chemicals unless specified were from
Sigma Aldrich (Poole, United Kingdom).
RNA Interference
Cells were seeded at a density to reach 30–50% confluence by the
day of transfection. Cells were transfected as described previously
(Alshaker et al., 2014, 2015) using siRNA directed against SK1
and SK2 as pooled four independent sequences and non-targeting
siRNA as a negative control combined with HiPerFect (Qiagen,
West Sussex, United Kingdom). Optimal knockdown (KD) was
obtained 72 h post-transfection and verified by qRT-PCR.
RNA Extraction, cDNA Synthesis and
qRT-PCR
Isolation of total RNA from cancer cells was performed using
the RNeasy Mini kit (Qiagen, Valencia, CA, United States)
as per manufacturer’s instructions. RNA quantity and purity
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FIGURE 1 | SK1/SK2 knockdown in prostate and breast cancer cell lines. Human breast cancer cell lines MDA-MB-231 and BT-549 and human prostate cancer
cells lines PC-3 and DU145 were transfected with SK1 and SK2 siRNA and gene knockdown was assessed by qRT-PCR (A,B). SK1 and SK2 activity was assessed
using radiolabeling assay (C,D). Data mean values of at least three independent experiments normalized to control ± SEM. ∗∗p < 0.01, ∗∗∗p < 0.001.
was measured using a NanoDrop 2000c Spectrophotometer
(Thermo Fisher Scientific, Loughborough, United Kingdom).
Reverse transcription was performed using Precision
nanoScriptTM Reverse transcription kit (PrimerDesign Ltd.,
Southampton, United Kingdom). qRT-PCR was done as
already described (Alshaker et al., 2014, 2017). Ct values were
exported and analyzed using qbase software (Biogazelle NV,
Zwijnaarde, Belgium).
RNA Microarray
RNA was normalized to an input amount of 99.9 ng and
underwent reverse transcription. sscDNA was purified using
magnetic beads and fragmented using UDG. Fragmented sample
was hybridized to Affymetrix Clariom S human arrays at 45◦C
overnight. Stained arrays are scanned to generate intensity data.
All reagent kits and arrays were purchased from Thermo Fisher
Scientific, Loughborough, United Kingdom.
Sphingosine Kinase Activity
Sphingosine kinases 1 and 2 assay was performed using
radiolabeling as previously described (Pchejetski et al., 2011;
Alshaker et al., 2014, 2015), in conditions favoring either SK1 or
SK2 activity (Liu et al., 2000).
Statistical Analysis
qRT-PCR data are presented as the mean values of at least
three independent experiments normalized to control± standard
error of the mean (SEM) calculated using GraphPad Prism.
Statistical significance between two groups was conducted
by unpaired Student’s t-test. P-value of <0.05 is considered
statistically significant.
DNA microarray analyses were performed in R version
3.4.3. Gene-level signal estimates were derived from CEL files
generated from Affymetrix Clariom S human arrays using
the multi-array analysis (RMA) algorithm (Irizarry et al.,
2003) implemented in Bioconductor package oligo version
1.42.0 (Carvalho and Irizarry, 2010). Differential expression
analysis was performed using the limma version 3.34.4: linear
models were determined for each transcript cluster (gene)
and an estimate for the global variance calculated by an
empirical Bayes approach (Smyth, 2004). A moderated t-statistic
was computed for each transcript cluster with the resulting
p-values adjusted for multiple testing using Benjamini and
Hochberg’s method to control the false discovery rate. Those
transcript clusters with an adjusted p-value less than 0.05
were considered to be significantly differentially expressed
between the two groups.
Gene ontology biological process and hallmarks of cancer
gene sets were tested in gene set enrichment analysis using
the clusterProfiler package, version 3.6 (Yu et al., 2012). The
t-statistic generated in the differential expression analyses was
used as the metric, with all entrez genes as the background
and a cut-off p-value of 0.05 after multiple testing using the
false discovery rate.
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FIGURE 2 | Altered gene expression in response to SK1 knockdown (KD) in prostate cancer cell lines. Human prostate cancer cells lines PC-3 and DU145 were
transfected with SK1 siRNA and Affymetrix Clariom S human array was performed as described in materials and methods. Differential expression analysis was
performed using the limma version 3.34.4: linear models were determined for each transcript cluster (gene) and an estimate for the global variance calculated by an
empirical Bayes approach. A moderated t-statistic was computed for each transcript cluster with the resulting p-values adjusted for multiple testing using Benjamini
and Hochberg’s method to control the false discovery rate. Those transcript clusters with an adjusted p-value less than 0.05 were considered to be significantly
differentially expressed between the two groups; bars, SEM.
RESULTS
Chemotherapy and molecular therapy are currently used in
treatment of locally advanced and metastatic prostate and
breast cancers. Among those cancers, androgen-independent
prostate tumors and triple negative breast tumors are considered
the most aggressive form of the disease. As a model of
those diseases, we have chosen two metastatic androgen-
insensitive prostate cancer cells lines PC-3 and DU145 and
two metastatic triple negative breast cancer cell lines MBA-
MB-231 and BT-549. SK1 and SK2 downregulation was
achieved by transfection with four pooled sequences siRNA
(Qiagen) for 72 h and verified using qRT-PCR (Figure 1).
It is interesting to note that in PC-3 and BT-549 cells KD
of SK1 caused a significant increase in SK2 expression (55
and 45%, respectively), however this effect was not present
in MDA-MB-231 and DU145 cells (Figure 1). These results
were confirmed on the enzyme level using SK1 and SK2
activity (Figure 1).
DNA CHIP analysis was performed on all samples in
triplicate using Affymetrix Clariom S microarray. Genes
were determined to be significantly differentially expressed
using a moderated t-test (p ( 0.05; Benjamin Hochberg
multiple testing correction applied). SK1 and SK2 regulated
genes exhibited tissue specific differences. As expected,
SK1 and SK2 were shown to be down-regulated by
respective siRNA pools (for clarity, these effects are not
shown in Figures 2–5).
In prostate cancer cells SK1 KD induced downregulation
of expression of ten genes and upregulation of five genes
(Figure 2, only genes identically regulated in both cell lines
are shown). Among the genes downregulated by SK1 were
G3BP stress granule assembly factors G3BP1 and G3BP2
[involved in nuclear factor kappa B (NFκB), RAS and Wnt
signaling], phosphoribosyl pyrophosphate synthetase 2 (PRPS2),
involved in multiple biosynthesis pathways like purine synthesis,
NOP2/Sun RNA methyltransferase family member 2 (NSUN2)
which regulates mRNA translation and NADH:ubiquinone
oxidoreductase subunit A2 (NDUFA2), a subunit of complex I
of the respiratory chain. SK1 KD increased expression of IBTK
(inhibitor of Bruton tyrosine kinase) and notably ETS1 (ETS
proto-oncogene 1, transcription factor).
In breast cancer cells SK1 KD (Figure 3) has decreased
the expression of E2F5 (E2F transcription factor 5), NSUN2,
nuclear factor of activated T-cells 3 (NFATC3) which regulates
transcription, PRPS2, cyclin dependent kinase 2 (CDK2), known
regulator in the cell cycle, G3BP stress granule assembly factors
G3BP1 and G3BP2, vesicle-associated membrane-protein-
associated protein B (VAPB) involved in vesicle trafficking and
N-acetylglucosamine kinase (NAGK), involved in metabolism.
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FIGURE 3 | Altered gene expression in response to SK1 knockdown (KD) in breast cancer cell lines. Human breast cancer cell lines MDA-MB-231 and BT-549 were
transfected with SK1 siRNA and Affymetrix Clariom S human array was performed as described in materials and methods. Differential expression analysis was
performed using the limma version 3.34.4: linear models were determined for each transcript cluster (gene) and an estimate for the global variance calculated by an
empirical Bayes approach. A moderated t-statistic was computed for each transcript cluster with the resulting p-values adjusted for multiple testing using Benjamini
and Hochberg’s method to control the false discovery rate. Those transcript clusters with an adjusted p-value less than 0.05 were considered to be significantly
differentially expressed between the two groups; bars, SEM.
SK1 KD has notably increased expression of RAB23 (encodes a
small GTPase of the RAS oncogene superfamily).
In prostate cells, SK2 KD affected expression of 25 genes
(Figure 4) including downregulation of capping actin protein of
muscle Z-line alpha subunit 1 (CAPZA1), involved in inhibition
of autophagy and epithelial-mesenchymal transition (EMT),
NSUN3 (NOP2/Sun RNA methyltransferase family member 3,
mRNA translation), ADP dependent glucokinase (ADPGK),
involved in EMT in cancer cells and kelch domain containing 10
(KLHDC10), which regulates oxidative stress. SK2 KD increased
expression of voltage dependent anion channel 1 (VDAC1)
oncogene, regulator of mammalian target of rapamycin (mTOR),
inhibitor of Bruton tyrosine kinase (IBTK), antiproliferative,
ataxin 10 (ATXN10) which activates the RAS-MAP kinase
pathway, ETS proto-oncogene 1 (ETS1), transcription factor,
ubiquitin conjugating enzyme E2 R2 (UBE2R2) involved in
ubiquitination and cell differentiation, MAP kinase interacting
serine/threonine kinase 2 (MKNK2), protein phosphatase 2
regulatory subunit B′alpha (PPP2R5A) and WEE1 G2 checkpoint
kinase (WEE1), cell cycle regulator.
On the other hand, SK2 KD in breast cancer (Figure 5)
has downregulated expression of integrin subunit alpha V
(ITGAV), belongs to the integrin alpha chain family which
may regulate angiogenesis and cancer progression and capping
actin protein of muscle Z-line alpha subunit 1 (CAPZA1),
regulates growth of the actin filament and increased expression
of general transcription factor IIB (GTF2B), zinc finger
DHHC-type containing 20 (ZDHHC20) and ST13, Hsp70
interacting protein, involved in the assembly process of
glucocorticoid receptor.
We have then performed a functional analysis of identified
genes for the gene-set enrichment of known biochemical
pathways upon SK1 and 2 KD. We have investigated the
changes for gene ontology biological process pathways
(Figure 6 and Supplementary Tables S1–S4) and hallmarks
of cancer gene sets (Tables 1–4). SK1 and SK2 KD had
different effect on pathway enrichment which was also
cell line dependent, although there were several common
pathways shared between both cell lines and both SKs. Gene-
set enrichment analysis of gene ontology biological process
enrichment pathways showed that in prostate cancer cells
SK1 KD has induced downregulation of pathways linked
with DNA conformation change, chromatin assembly and
regulation of G1/S transition of mitotic cell cycle and notably
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FIGURE 4 | Altered gene expression in response to SK2 knockdown (KD) in prostate cancer cell lines. Human prostate cancer cells lines PC-3 and DU145 were
transfected with SK2 siRNA and Affymetrix Clariom S human array was performed as described in materials and methods. Differential expression analysis was
performed using the limma version 3.34.4: linear models were determined for each transcript cluster (gene) and an estimate for the global variance calculated by an
empirical Bayes approach. A moderated t-statistic was computed for each transcript cluster with the resulting p-values adjusted for multiple testing using Benjamini
and Hochberg’s method to control the false discovery rate. Those transcript clusters with an adjusted p-value less than 0.05 were considered to be significantly
differentially expressed between the two groups; bars, SEM.
enrichment of Wnt signaling pathway, cell motility and
MAP kinase activity (Supplementary Table S1, examples
of linked pathways shown in Figure 6). In breast cancer
cells SK1 KD has induced a downregulation of pathways
responsible for DNA replication and repair, cell cycle (G1/S),
p53, enrichment in Wnt signaling and vesicle-mediated
transport pathways (Supplementary Table S2, examples of
linked pathways shown in Figure 6). In prostate cancer cells,
SK2 KD has enriched RAS protein signal transduction, MAP
kinase, protein serine/threonine kinase, cell motility, small
GTPase and phosphatidylinositol 3-kinase signaling pathways
(Supplementary Table S3, examples of linked pathways
shown in Figure 6) while in breast cancer cells it induced
Wnt signaling, small GTPase mediated signal transduction,
MAP kinase, endosomal transport and RAS protein signal
transduction pathways and downregulated DNA repair pathway
(Supplementary Table S4, examples of linked pathways
shown in Figure 6).
Gene-set enrichment analysis of hallmarks of cancer pathways
has shown several important pathways regulated by SK1/SK2 KD.
SK1 KD in breast cancer cell lines downregulated Myc, G2/M
cell cycle and E2F pathways (Table 1) and upregulated KRAS,
IL2/signal transducer and activator of transcription (STAT)5
and tumor necrosis factor (TNF)/NFκB pathways. Prostate
cancer cell lines similarly had G2/M, E2F and additionally
p53 pathways downregulated, and KRAS, IL2/STAT5,
TNF/NFκB and additionally EMT pathways upregulated
by SK1 KD (Table 2).
Sphingosine kinase 2 KD had similar effects to SK1 in breast
cancer cells downregulating KRAS, G2/M and E2F pathways and
upregulating EMT and p53 pathways (Table 3). On the contrary,
in prostate cancer cells SK2 KD has upregulated G2/M and E2F
pathways (Table 4).
DISCUSSION
In the last decade SK inhibitors have shown significant potential
for cancer treatment. There are dozens of papers proving
their antitumour efficacy in vitro and in vivo (reviewed in
Alshaker et al., 2013) and two molecules are already in clinical
trials: SK1 inhibitor phenoxodiol (Veyonda) for prostate cancer,
non-small cell lung cancer and sarcoma; and SK2 inhibitor
ABC294640 (opaganib) for advanced solid tumors and multiple
myeloma. These inhibitors are often proposed to be used as
“sensitisers” to chemo- and radiotherapy and can be used as
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FIGURE 5 | Altered gene expression in response to SK2 knockdown (KD) in breast cancer cell lines. Human breast cancer cell lines MDA-MB-231 and BT-549 were
transfected with SK2 siRNA and Affymetrix Clariom S human array was performed as described in materials and methods. Differential expression analysis was
performed using the limma version 3.34.4: linear models were determined for each transcript cluster (gene) and an estimate for the global variance calculated by an
empirical Bayes approach. A moderated t-statistic was computed for each transcript cluster with the resulting p-values adjusted for multiple testing using Benjamini
and Hochberg’s method to control the false discovery rate. Those transcript clusters with an adjusted p-value less than 0.05 were considered to be significantly
differentially expressed between the two groups; bars, SEM.
free drugs or in nanoparticle settings (Alshaker et al., 2017;
Wang et al., 2017; Yee et al., 2017). Their specificity has
significantly increased with the recent discovery of SK1 structure
(Wang et al., 2013) and the use of computer modeling methods
(Alshaker et al., 2018).
Cancer progression is mediated by multiple mutations and
involves activation of a wide variety of signaling pathways, many
of which are cross-regulated or lead to similar downstream
events (reviewed in Garland, 2017). For example, in cancer cell,
a mutation in receptor tyrosine kinase can activate multiple
signaling pathways and subsequent transcription factors leading
to gene expression, while each of these pathways can be
also mutated or activated independently, creating a highly
complex web of signaling. The typical molecular targeting
therapy approach is to block these pathways (e.g., tyrosine
kinases, mTOR, MAPK, PARP, CDK, etc.) with specific inhibitors.
Aside from few cases (such as BCR-Abl), where one major
mutation is responsible for cancer progression, it appears
that switching off one pathway is usually insufficient to
completely block cancer cell growth and induce cell death.
Ordinarily, targeted cancer monotherapy can end up with bypass
mechanisms. Resistant clones of cancer cells evolve that can
compensate for the switched off pathway by upregulating other
independent pathways.
Several approaches can be used to circumvent this
phenomenon. First, improved drug delivery may allow
achieving higher drug concentrations in the tumor leading
to higher efficacy. Second, the employment of several
combined targeted or non-targeted therapies or agents
that interfere with multiple cell-signaling pathways may
allow making multiple hits on the cell proliferation
machinery. Finally, a combination of these approaches
can possibly provide a significant benefit both in terms of
efficacy and reducing side effects (Alshaker et al., 2017;
Wang et al., 2017).
When designing the successful drug combinations, one may
consider which pathways are implicated in proliferation and
chemoresistance in the target system, as well as the known
crosstalk between these pathways. For example, if a pro-survival
pathway A activates a pro-survival pathway B, but doesn’t
affect the pro-survival pathway C, targeting both A and B
is redundant while targeting A and C may have synergistic
therapeutic effect.
We have conducted this study to identify which signaling
pathways are universally or tissue specifically regulated by SK1
and SK2 in prostate and breast cancers. More importantly,
we questioned which common cell proliferation pathways
are upregulated as compensatory mechanisms and may be
responsible for resistance to anti-SK therapies. Considering that
SK inhibitors may reach clinic in near future, this knowledge
would allow us to hypothesize which combinational therapies
may have synergistic effects.
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FIGURE 6 | Gene-set enrichment analysis of gene ontology biological process enrichment pathways. Human prostate cancer cells lines PC-3 and DU145 (A,B) and
human breast cancer cell lines MDA-MB-231 and BT-549 (C,D) were transfected with SK1 (A,C) and SK2 (B,D) siRNA and Affymetrix Clariom S human array was
performed as described in materials and methods. Gene ontology biological process and hallmarks of cancer gene sets were tested in gene set enrichment analysis
using the clusterProfiler package, version 3.6. The t-statistic generated in the differential expression analyses was used as the metric, with all Entrez Genes as the
background and a cut-off p-value of 0.05 after multiple testing using the false discovery rate.
Across all four cell lines investigated SK1 KD downregulated
expression of NSUN2 (mRNA translation), PRPS2 (purine
synthesis) and G3BP1,2 (NFκB, RAS, and Wnt signaling)
(Figures 2, 3). Other notable genes decreased by SK1 KD were
NDUFA2 in prostate and E2F5, NAGK, VAPB, NFATC3, CDK2
in breast cancer cell lines. SK2 KD universally downregulated
expression of CAPZA1 (inhibition of autophagy and EMT) and
also decreased expression of NSUN3, ADPGK and KLHDC10
in prostate and ITGAV in breast cancer cell lines (Figures 4, 5).
From these data it appears that SK targeting carries a significant
antiproliferative effect through downregulation of expression of
several genes which are relevant for cell survival and division.
However, individually SK1 and SK2 KD have led to upregulation
of multiple genes (IBTK, GTF2B, VDAC1, GTF2B, ETS1, TTC17,
IBTK, ZDHHC20, RAB23, ATXN10, ST13, ETS1, PPP2R5A,
MKNK2, UBE2R2, WEE1) that regulate transcription, cell cycle,
EMT, cell motility, serine/threonine kinases, small GTPases,
phosphatidylinositol 3-kinase (PI3K), HSP70, Wnt, mTOR, RAS
and MAPK signaling pathways (Jiang-Hua et al., 2014; Hu
et al., 2018; Liu et al., 2018). It is very likely that these
pathways represent a cellular “compensatory” response and may
be potentially contributing to SK-inhibitor resistance.
Sphingosine kinases 1 and 2 KD has up- and downregulated
a significant number of genes in individual cell lines
(Supplementary Table S5). This number was reduced to 15
and 25 genes for SK1 and SK2 KD, respectively, in prostate
cells and 25 and 8 genes for SK1 and SK2 KD, respectively,
in breast cancer cells (Figures 2–5, 7). There was some
concordance of SK-regulated genes between the tissues. Five
genes (DPH2 G3BP1, G3BP2, NSUN2, and TTC17) were
similarly regulated by SK1 KD in prostate and breast cancer
cells (Figure 7). SK2 KD has regulated CAPZA1, ELMOD2,
and HACD2 in a similar fashion across all four cell lines
(Figure 7). There was no overlap between SK1 and SK2
regulated genes.
While individual genes may provide insight into altered
signaling, gene-set enrichment analysis may demonstrate a
bigger picture of significant pathways modulated by SK KD.
Gene-set enrichment pathway analysis showed that in all cell
lines SK1 KD decreased DNA conformation and replication
pathways, while SK2 KD did not decrease any major pro-
proliferative pathways. In contrast, there is a clear concordance
in pathways upregulated in response to SK KD. SK2 KD has
upregulated RAS, MAPK and small GTPase pathways, while
Frontiers in Pharmacology | www.frontiersin.org 8 March 2019 | Volume 10 | Article 303
fphar-10-00303 March 25, 2019 Time: 18:14 # 9
Alshaker et al. Therapeutic Targeting of Sphingosine Kinase
TABLE 1 | Gene-set enrichment analysis of hallmark of cancer enrichment
pathways in response to SK1 KD in breast cancer cells.
Description Enrichment score p-value
HALLMARK_E2F_TARGETS −0.58603 0.001923
HALLMARK_G2M_CHECKPOINT −0.45283 0.001905
HALLMARK_MYC_TARGETS_V1 −0.40462 0.001923
HALLMARK_UV_RESPONSE_UP
-0.32927
0.012121
HALLMARK_INFLAMMATORY_
RESPONSE
0.285129 0.026971
HALLMARK_KRAS_SIGNALING_UP 0.287628 0.024896
HALLMARK_IL2_STAT5_SIGNALING 0.296696 0.010526
HALLMARK_APOPTOSIS 0.300881 0.026
HALLMARK_GLYCOLYSIS 0.30635 0.004149
HALLMARK_TNFA_SIGNALING_VIA_
NFKB
0.314365 0.004211
HALLMARK_COMPLEMENT 0.32964 0.004211
HALLMARK_APICAL_JUNCTION 0.340443 0.002075
HALLMARK_MYOGENESIS 0.34409 0.002105
HALLMARK_P53_PATHWAY 0.354588 0.002096
HALLMARK_HYPOXIA 0.355858 0.002105
HALLMARK_FATTY_ACID_
METABOLISM
0.373058 0.003984
HALLMARK_XENOBIOTIC_
METABOLISM
0.374965 0.002075
HALLMARK_ADIPOGENESIS 0.381432 0.002105
HALLMARK_COAGULATION 0.404393 0.001996
HALLMARK_INTERFERON_GAMMA_
RESPONSE
0.4096 0.00211
HALLMARK_EPITHELIAL_
MESENCHYMAL_TRANSITION
0.414758 0.002105
HALLMARK_UV_RESPONSE_DN 0.437977 0.001976
TABLE 2 | Gene-set enrichment analysis of hallmark of cancer enrichment
pathways in response to SK1 KD in prostate cancer cells.
Description Enrichment score p-value
HALLMARK_UV_RESPONSE_UP −0.402737052 0.0027
HALLMARK_E2F_TARGETS −0.382852104 0.0028
HALLMARK_G2M_CHECKPOINT 0.373919221 0.0028
HALLMARK_P53_PATHWAY −0.311816056 0.0028
HALLMARK_XENOBIOTIC_METABOLISM −0.31162798 0.0028
HALLMARK_INTERFERON_GAMMA_
RESPONSE
−0.308977776 0.0028
HALLMARK_FATTY_ACID_METABOLISM −0.290319736 0.0134
HALLMARK_ADIPOGENESIS −0.290165971 0.0057
HALLMARK_OXIDATIVE_
PHOSPHORYLATION
−0.273082408 0.0113
HALLMARK_COMPLEMENT 0.283316334 0.0246
HALLMARK_HYPOXIA 0.291083127 0.0185
HALLMARK_IL2_STAT5_SIGNALING 0.295293643 0.0154
HALLMARK_TNFA_SIGNALING_VIA_
NFKB
0.317881573 0.0077
HALLMARK_MITOTIC_SPINDLE 0.333397383 0.0046
HALLMARK_KRAS_SIGNALING_UP 0.367158279 0.0015
HALLMARK_EPITHELIAL_
MESENCHYMAL_TRANSITION
0.440097468 0.0015
TABLE 3 | Gene-set enrichment analysis of hallmark of cancer enrichment
pathways in response to SK2 KD in breast cancer cells.
Description Enrichment score p-value
HALLMARK_INTERFERON_GAMMA_
RESPONSE
−0.389698297 0.0043
HALLMARK_ALLOGRAFT_REJECTION −0.339536274 0.0043
HALLMARK_KRAS_SIGNALING_DN −0.28487173 0.0042
HALLMARK_E2F_TARGETS −0.278165758 0.0085
HALLMARK_G2M_CHECKPOINT −0.270306348 0.0129
HALLMARK_GLYCOLYSIS 0.317865223 0.0222
HALLMARK_FATTY_ACID_METABOLISM 0.326776858 0.0214
HALLMARK_MITOTIC_SPINDLE 0.348623881 0.0052
HALLMARK_XENOBIOTIC_METABOLISM 0.356201125 0.0013
HALLMARK_HYPOXIA 0.356508267 0.0013
HALLMARK_APICAL_JUNCTION 0.356988995 0.0013
HALLMARK_EPITHELIAL_
MESENCHYMAL_TRANSITION
0.373510215 0.0013
HALLMARK_ADIPOGENESIS 0.382867908 0.0013
HALLMARK_HEME_METABOLISM 0.390882683 0.0013
HALLMARK_P53_PATHWAY 0.424168593 0.0013
HALLMARK_MYOGENESIS 0.429404077 0.0013
HALLMARK_UV_RESPONSE_DN 0.445254468 0.0014
TABLE 4 | Gene-set enrichment analysis of hallmark of cancer enrichment
pathways in response to SK2 KD in prostate cancer cells.
Description Enrichment score p-value
HALLMARK_INTERFERON_GAMMA_
RESPONSE
−0.45775 0.003021148
HALLMARK_UV_RESPONSE_UP −0.35239 0.002881844
HALLMARK_FATTY_ACID_
METABOLISM
−0.30608 0.00877193
HALLMARK_HEME_METABOLISM 0.3308 0.004470939
HALLMARK_E2F_TARGETS 0.33106 0.004451039
HALLMARK_G2M_CHECKPOINT 0.34475 0.001501502
HALLMARK_UV_RESPONSE_DN 0.3727 0.003120125
HALLMARK_MITOTIC_SPINDLE 0.47889 0.00148368
SK1 KD has increased Wnt signaling in all four cell lines
(Supplementary Tables S1–S4). In tissue specific manner, SK1
and SK2 KD individually have also increased cell motility,
vesicular transport, cell motility, Rho, PI3K and serine/threonine
kinase pathways. Similar to individual genes, these pathways
are likely to represent the “compensatory” response of cancer
cells to SKs KD and may contribute to developing resistance for
anti SK therapies.
Gene-set enrichment analysis of hallmarks of cancer pathways
has shown that several important pathways are upregulated
in response to SK1/SK2 KD, most notably KRAS, IL2/STAT5,
EMT and TNF/NFκB (SK1 KD) and EMT, G2/M and E2F (SK2
KD) (Tables 1–4). Interestingly, several well-known pathways
implicated in cancer progression or apoptosis were unaffected
by SK KD (such as BCL2, PARP, or many transcription factors).
These pathways are also therapeutic targets and concurrent
Frontiers in Pharmacology | www.frontiersin.org 9 March 2019 | Volume 10 | Article 303
fphar-10-00303 March 25, 2019 Time: 18:14 # 10
Alshaker et al. Therapeutic Targeting of Sphingosine Kinase
FIGURE 7 | Venn diagram of genes regulated by SK1/SK2 knockdown (KD) in prostate and breast cell lines. Human breast cancer cell lines MDA-MB-231 and
BT-549 and prostate cancer cells lines PC-3 and DU145 were transfected with SK1 or SK2 siRNA and Affymetrix Clariom S human array was performed as
described in materials and methods. Numbers of significantly regulated genes common to prostate or breast cell lines are shown in outer semicircles and the
number of genes universally regulated by SK1 or SK2 KD in all cell lines is shown in the middle. These universal genes are listed below the circles.
use of their inhibitors and SK inhibitors may have therapeutic
advantage. For example, if one were to use SK1 inhibitor in
prostate cancer, adding PI3K inhibitor may be of particular
benefit as SK1 KD is upregulating PI3K pathway which may
mediate resistance. Same goes for e.g., Ras pathway and SK2
in both prostate and breast cancer cells. Conversely G1/S and
G2/M are both significantly inhibited by SK1 KD in breast
cancer cells, therefore adding cell cycle inhibitors may be of no
additional benefit.
There were no previous studies investigating transcriptome
in response to SK1 KD. An opposite study was performed by
Pham et al. (2014), who have transfected NIH3T3 cells with
SK1 and analyzed transcriptome identifying multiple genes
regulated by artificially increased SK1. There, however, may
be significant difference between genes regulated by baseline
SK1 activity or its absence (as in our case) and artificial
SK1 overexpression. From comparison of both studies it is
also clear that SK1-regulated genes are tissue and cell line
specific. Angerer et al. (2018) have described transcriptome
profiling of peripheral blood immune cell populations in
multiple sclerosis patients before and during treatment with
a sphingosine-1-phosphate receptor modulator fingolimod
(also an SK1 inhibitor in higher doses) identifying QGAP2,
MYBL1, and PTPN12 that were consistently expressed
at significantly higher transcript levels in response to
continued administration of fingolimod in CD8+, CD4+
and CD19+ cells. Fingolimod has S1P receptor affinity at
nanomolar range but requires micromolar levels to inhibit
SK1 (Pchejetski et al., 2010), and it is unlikely that such
levels were achieved in human patients. In addition to
designing combined therapies, our data may also provide
an insight into the potential side effects of therapeutic SKs
inhibition. Many of the identified pathways are linked with tissue
development, DNA repair, apoptosis and many other pivotal
physiological processes.
As any pharmacological compounds, most SK inhibitors
are not uniquely targeting SKs. Some of them have higher
affinity toward SK1 (e.g., SK1-I) or SK2 (e.g., ABC294640),
while others inhibit both SKs (e.g., SKI-II). They may also
affect activity of other kinases. We therefore focused on using a
“clean method” of SKs downregulation. It is, however, possible
that siRNAs may have different effect on gene expression than
pharmacological inhibitors.
CONCLUSION
Through genome-wide microarray, we have identified important
molecular pathways affected and not affected by SK1 and
SK2 signaling. Multiple pathways such RAS, MAPK, small
GTPase, Wnt and PI3K were upregulated in response to SK
KD. Additionally, several well-known pathways implicated in
cancer progression or apoptosis were unaffected by SK KD
(such as BCL2, PARP). Co-targeting of these pathways may
present a viable therapeutic option to overcome SK inhibitor
resistance in prostate and breast cancer. Further signaling studies
are required to confirm the individual involvement of the
identified pathways.
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